The maintenance of an Outperform rating suggests that RBC Capital still sees Viracta Therapeutics as a stock likely to perform better than the broader market. However, the reduction in the price target could reflect a reassessment of the company's near-term growth prospects or market conditions, leading to a neutral short-term impact on the stock price as investors digest the mixed signals.